Ciprofloxacin
Pseudomonas Aeruginosa Infectious Disease
Explore 5 assets in Pseudomonas Aeruginosa Infectious Disease →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03262142CT.gov Targeted AntiBiotics for Chronic Pulmonary Diseases | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pseudomonas Aeruginosa Infectious Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ciprofloxacin (this asset) | Chronic Obstructive Pulmonary Disease Trial Network, Denmark | Approved | B · 62 |
| Ap-Pa02 | Armata Pharmaceuticals, Inc. | P2 | BB |
| Aztreonam Lysine | Gilead Sciences | P3 | BB |
| Piperacillin | Chronic Obstructive Pulmonary Disease Trial Network, Denmark | P4 | BB |
| Ceftolozane | Sunshine Coast Hospital and Health Service | P4 | BB |
| Tazobactam | Sunshine Coast Hospital and Health Service | P4 | BB |
| Pseudomonas Aeruginosa-Specific Bacteriophage Mixture, Live Consisting Of 3 Bacteriophages (Ihma-2121771-1, Ihma-2121771-2, Ihma-2121908-1) | BiomX Ltd | P2 | BB |
| Ceftazidime | Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche | P4 | B |
| Aztreonam | Gilead Sciences | P2 | B |
+4 more in the Pseudomonas Aeruginosa Infectious Disease cohort
Other indications for Ciprofloxacin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bronchiectasis | — | P4 | BBB · 76 |
| Infectious Disease | — | P4 | BBB · 72 |
| Chronic Obstructive Pulmonary Disease | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ciprofloxacin in Pseudomonas Aeruginosa Infectious Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/ciprofloxacin-pseudomonas-aeruginosa-infectious-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →